Home/Stocks/Pharmaceuticals

AstraZeneca PLC

AZN·Pharmaceuticals·Market Cap £234.3b

Rank #11 of 48

Data from Excel Model · 48 Stocks Analysed

£151.10

+9.57% YTD

Target: £157.69(+4.4%)

52W: £95.74 - £157.30

Score Analysis

AstraZeneca PLC is ranked #11 out of 48 UK stocks. Lower factor scores indicate better performance in that category.

Factor Breakdown

28/48

Average Score

Liquidity

Weak33/48

Valuation

Weak38/48

Profitability

Weak46/48

Solvency

Excellent7/48

Mkt Trading

Weak34/48

Technical

Excellent8/48

1. Valuation

Score: 38/48

Is AZN undervalued compared to its peers and fair value metrics?

1/5

valuation criteria met

✗

FY26e P/E Ratio

19.8xRank 36/48

✗

FY27e P/E Ratio

17.6xRank 35/48

✗

Price-to-Book

6.49xRank 35/48

✓

Price-to-Tangible Book

N/ARank 1/48

✗

EV/EBITDA

17.3xRank 40/48

Key Valuation Metrics

Current P/E

30.8x

Price-to-Earnings

FY26e P/E

19.8x

Forward estimate

FY27e P/E

17.6x

Forward estimate

P/B Ratio

6.49x

Price-to-Book

P/TBV

N/A

Price-to-Tangible Book

EV/EBITDA

17.3x

Enterprise Value

FY26e EV/EBITDA

15.0x

Forward estimate

FY27e EV/EBITDA

13.7x

Forward estimate

Analyst Consensus Target

Current Price

£151.10

Consensus Target

£157.69

Potential

+4.4%

Target

Bloomberg Median Target: £162.34

2. Profitability

Score: 46/48

How profitable is AZN relative to its peers?

0/6

profitability criteria met

✗

TTM Profit Margin

17.4%Rank 34/48

✗

Current ROE

22.9%Rank 36/48

✗

Current ROA

9.4%Rank 37/48

✗

FY26e EPS

10.30Rank 48/48

✗

TTM EPS

6.60Rank 45/48

✗

Net Income Growth

Rank 49Rank 49/48

Profit Margin

17.4%

ROE

22.9%

FY27e ROE

26.2%

ROA

9.4%

Earnings Per Share

3. Financial Health

Score: 7/48

How strong is AZN's balance sheet and financial position?

2/6

solvency criteria met

✗

Debt-to-Equity

60.8%Rank 35/48

✓

Altman Z-Score

4.77Rank 12/48

✗

Z-Score Trend

Rank 49Rank 49/48

✗

Amihud Illiquidity

Rank 49Rank 49/48

✗

Intangible/Asset

Rank 49Rank 49/48

✓

R&D/Sales

Rank 1Rank 1/48

Key Health Metrics

Quick Ratio

0.52

Below 1.0

Cash Ratio

0.19

Debt/Equity

61%

FCF Margin

3.8%

Altman Z-Score

4.77

Safe Zone

01.812.995+

4. Dividend

AZN pays a dividend yield of 1.58%.

Current Yield

1.58%

FY27e Yield

1.64%

FY26e DPS

3.345

FY27e DPS

N/A

Dividend Per Share Forecast

5. Technical Analysis

Score: 8/48

What do the technical indicators say about AZN?

3/4

technical criteria met

✓

CMP vs 52W High

-3.9%Rank 19/48

✗

CMP vs 52W Low

57.8%Rank 23/48

✓

RSI 14 Day

61.1Rank 18/48

✓

MA(50) > MA(200)

Yes (Bullish)Rank 1/48

RSI (14 Day)

61.1

Bullish

0 (Oversold)50100 (Overbought)

Moving Averages

MA 30-Day£143.52

MA 50-Day£141.46

MA 200-Day£123.52

SignalGolden Cross (Bullish)

MACD386.11

Risk Metrics

Beta

1.08

Higher volatility

3-Yr Std Dev

1245.7%

5-Yr Std Dev

1748.3%

6. Market Trading

Score: 34/48

How liquid and actively traded is AZN?

1/4

market trading criteria met

✗

5D Avg Volume

1.3MRank 35/48

✗

3M Avg Volume

1.3MRank 35/48

✗

Volume Trend

-1.0%Rank 49/48

✓

Beta

1.08Rank 19/48

Shares Outstanding

1550.9m

Free Float

96.7%

Enterprise Value

$339.7b

Trading Volume

7. Peer Comparison

How does AZN compare to other Pharmaceuticals stocks?

Overall Rank Comparison

Factor Score Comparison

Stock	Rank	Liquidity	Valuation	Profitability	Solvency	Mkt Trading	Technical
AZN	#11	33	38	46	7	34	8
GSK	#12	24	13	39	6	11	22

Similar Stocks

Other top-ranked stocks in the Pharmaceuticals sector